European Society for Radiotherapy and Oncology (ESTRO)’s Post

Have you seen the latest International Stereotactic Radiosurgery Society (ISRS) guideline? Take a moment to list to this great podcast with author and ISRS Member Shankar Siva ⬇ ⬇

In the ever-evolving field of radiation oncology, staying current with the latest research and evidence is crucial. A groundbreaking step in this direction is the development of TrialsSummarizer, an innovative system designed to automatically generate summaries from randomized controlled trials

In the ever-evolving field of radiation oncology, staying current with the latest research and evidence is crucial. A groundbreaking step in this direction is the development of TrialsSummarizer, an innovative system designed to automatically generate summaries from randomized controlled trials

In the ever-evolving field of radiation oncology, staying current with the latest research and evidence is crucial. A groundbreaking step in this direction is the development of TrialsSummarizer, an innovative system designed to automatically generate summaries from randomized controlled trials

In the ever-evolving field of radiation oncology, staying current with the latest research and evidence is crucial. A groundbreaking step in this direction is the development of TrialsSummarizer, an innovative system designed to automatically generate summaries from randomized controlled trials

The authors focus on the role of surgical resection for small bowel neuroendocrine tumors (SB-NETs) in this Annals of Surgical Oncology #FeaturedArticle. 📃: https://lnkd.in/e9PRyAg

While at #ASTRO24, Vaseem Khatri, MD shared insight from a multi-institutional report of trastuzumab-deruxtecan and stereotactic radiosurgery for HER2+ #BreastCancer brain metastases. Learn more ➡️ https://lnkd.in/eP8s-_tA American Society for Radiation Oncology (ASTRO) #MoffittASTRO24

ASTRO ACADEMY WEBINAR - Wednesday, September18, 2024, 2 - 3:30 PM https://lnkd.in/e7BwBDWy Hot Topic : An Overview of the Multidisciplinary Management of Dupuytren's and Ledderhose Diseases byGopal Bajaj, MD, MBA, FASTRO and M. Heinrich Seegenschmiedt, MD, PhD moderated by  Bobby N. Koneru, MD, FASTRO Dupuytren's and Ledderhose Diseases are very prevalent hyperproliferative disorders of the hands and feet that affect 3-5% of the population. When progressive, these conditions can result in pain, debility and loss of function. Radiation therapy is commonly utilized in Europe for the treatment of both of these conditions but much less commonly employed in North America. This session will review the pathophysiology, diagnosis and management of Dupuytren's and Ledderhose Diseases and provide an overview of the expanding role of the radiation oncologist in the longitudinal and multidisciplinary management of these patients. The following topics will be addressed: Basic Defintions & Terms; Epidemiology & Etiology (GB) / Pathogenesis & Radiobiology, Clinical Exam & Assessment (MHS) / Classification & Staging; Treatment Options general and with minimal invasive and noninvasive methods (GB) / Role of Radiotherapy using a prophylactic and possibly an adjuvant / post-interventional approach; Clinical studies & results (HS) // The Patient Journey & Multi-Disciplinary Considerations (GB & MHS) plus Case Studies: DD and LD RT Treatments: Too Early / Too Late / Just Right / Adjuvant approach ? (MHS & GB) #ASTRO #ASTROAcademy #DupuytrenDisease #LedderhoseDisease #Radiotherapy #Radiobiology #Imaging #Multidisciplinary #ClinicalStudies

📢 New from Lancet Oncology: An assessment of global access to radiotherapy & theranostics! 🌍 Disparities remain, yet strides have been made since 2015. Read more here: https://lnkd.in/gM9pTPPZ

At #ASTRO24, Matthew Adams shares insight into #RadOnc provider perceptions and attitudes towards virtual tumor boards. The study assesses whether quality was maintained and if work-life balance improved. Learn more ➡️ https://lnkd.in/eA3pdRhu American Society for Radiation Oncology (ASTRO) #MoffittASTRO24